BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces the publication of its 2025 Universal Registration Document (URD) as filed with the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 23, 2026, under number D.26-0284. The Universal Registration D